Drug
Ly4336619
Ly4336619: highest development phase Phase 1, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY4336619 NCT07928258 | Phase 1 | Endometrial Neoplasms |
Latest
No recent events.
Follow Ly4336619 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.